Bone marrow-derived CD133+ vs. mononuclear cells for treatment of myocardial infarction

The aim of this study is to assess the efficacy of autologous bone marrow-derived hematopoietic CD133+ stem cells (BM-HSCs CD133+) in treating myocardial infarction, in comparison to that of marrow-derived mononuclear cells (BM-MNCs).